Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.

Toshiyuki WatanabeJun FukaeShinji FukayaNorifumi SawamukaiMasato IsobeMegumi MatsuhashiMasato ShimizuKazumasa AkikawaKazuhide TanimuraTatsuya AtsumiTakao Koike

Published in: International journal of rheumatic diseases (2018)

HBV reactivation occurred in 4.6% of RA patients with resolved HBV during the treatment with bDMARDs and the absence of anti-HBs may be a risk factor for the reactivation of resolved HBV.

Keyphrases

hepatitis b virus
rheumatoid arthritis
liver failure
disease activity
ankylosing spondylitis
interstitial lung disease
rheumatoid arthritis patients
systemic sclerosis